Prostate cancer, the second leading cause of cancer death in men, sees advancements in treatment that reduce side effects, ...

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Scientists have uncovered a critical weakness in prostate cancer’s defences. The disease relies on two enzymes, PDIA1 and ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

Prostate and skin cancers are among the most common cancers affecting men. In Advanced Prostate Cancer, lifelong treatment ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

The FDA-approved drug Pluvicto offers hope for advanced prostate cancer patients, but access barriers remain despite proven ...

NEW YORK (Reuters Health) - Men diagnosed with localized prostate cancer are more likely to be treated with proton beam therapy, a novel form of radiation therapy, if the technology is available ...

Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

Black men choose aggressive prostate cancer treatment—regardless of anticipated life expectancy—more often than Hispanic or ...